Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 10/20 | 0.42 |
| ▸ | MMP2 | P08253 | 10/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4229702 | 0.76 | CETP (0.38) | POLBMEN1KMT2A | |
| SCHEMBL4226835 | 0.75 | MMP3 (0.41) | MMP3MMP2HPGDLMNA | |
| SCHEMBL4225371 | 0.69 | MMP3 (0.51) | MMP3MMP2POLBMEN1KMT2A | |
| SCHEMBL7448460 | 0.64 | MMP3 (0.48) | MMP3MMP2HPGDMEN1KMT2A | |
| SCHEMBL4223008 | 0.63 | POLB (0.56) | MMP3MMP2POLBMEN1KMT2A | |
| SCHEMBL5068839 | 0.63 | POLB (0.56) | MMP3MMP2POLBMEN1KMT2A | |
| SCHEMBL13744635 | 0.63 | POLB (0.56) | MMP3MMP2POLBMEN1KMT2A | |
| SCHEMBL7700313 | 0.62 | TRPA1 (0.48) | MMP3MMP2HPGDMEN1KMT2A | |
| SCHEMBL473644 | 0.61 | MMP2 (0.61) | MMP3MMP2PTGESALOX5PPARG | |
| SCHEMBL8904812 | 0.60 | MMP2 (0.56) | MMP3MMP2HPGDPTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215780-A1 | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity | FABP4, GPR119, LIPC | MMP3 1010/4885MMP2 2227/4885HPGD 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.